Lensar Inc (LNSR) Stock Price, Quote & News

Company Profile

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cat...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 536 7271

Website: www.lensar.com

Address:

2800 Discovery Drive, Orlando, United States

ap20 Dec. 4 at 7:32 PM

$LNSR Buying back today. I don’t know much about the FTC, but just don’t think they care much about a $166M deal. We will see..

0 · Reply

BEATOFtheMARKET Nov. 25 at 8:02 PM

$LITE $LLY $LLYX $LMND $LNSR

0 · Reply

BEATOFtheMARKET Nov. 22 at 9:31 PM

$LITE $LLY $LLYX $LMND $LNSR

0 · Reply

RocketThief Nov. 7 at 3:59 PM

$LNSR now cheaper than when the Alcon deal was announced. Very interesting situation

1 · Reply

MarketCraze Oct. 5 at 10:18 AM

$LNSR Technology services niche. Thin volume trading. No technical edge. Avoid.

0 · Reply

NVDAMillionaire Sep. 9 at 8:30 AM

$LNSR Great piece that accurately captures LNSR's current position. So if you want to refresh your understanding of LNSR or learn about LNSR for the first time, this is essential reading. https://beyondspx.com/quote/LNSR/analysis/lensar-s-ally-system-precision-robotics-and-strategic-acquisition-reshape-cataract-surgery-nasdaq-lnsr

0 · Reply

RocketThief Aug. 14 at 8:00 PM

$LNSR nice spot for a small swing - would be surprised if the merger doesn’t happen

0 · Reply

d_risk Aug. 8 at 11:51 AM

$LNSR - LENSAR Inc. Common Stock - 10Q - Updated Risk Factors LNSR’s latest 10-Q risk factors spotlight major uncertainties around the Alcon merger—regulatory hurdles, FTC scrutiny, litigation threats, and strict deal terms that limit alternative bids. Expanded risks cover global economic pressures, supply chain and reimbursement challenges, intense competition, data privacy, and new ESG scrutiny, while detailing customer concentration, financing, and shareholder control issues. #MedicalDevices #ESG #SupplyChain #RegulatoryRisk #MergersAndAcquisitions 🟢 Added 🟠 Removed https://d-risk.ai/LNSR/10-Q/2025-08-07

0 · Reply

PenkeTrading Jun. 6 at 2:13 PM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of LENSAR Inc. Is that bullish or bearish? $LNSR #LENSAR #RsiOversold #NASDAQ

0 · Reply

HypnoTrader Jun. 5 at 6:58 PM

$LNSR merger caput?

0 · Reply

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

Sep 2, 2025, 4:01 PM EDT - 3 months ago

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 10:38 AM EDT - 4 months ago

Lensar (LNSR) Q2 Revenue Rises 10%

Aug 7, 2025, 7:00 AM EDT - 4 months ago

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

Jun 3, 2025, 5:23 PM EDT - 6 months ago

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

ALC

May 8, 2025, 7:00 AM EDT - 7 months ago

LENSAR Reports First Quarter 2025 Results and Provides Business Update

Feb 28, 2025, 1:05 PM EST - 10 months ago

LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 10 months ago

LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 19, 2025, 12:00 PM EST - 10 months ago

LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025

Feb 5, 2025, 4:36 AM EST - 11 months ago

Medical Devices Firm Lensar Surges Ahead On Robotic Technology

Nov 26, 2024, 8:00 AM EST - 1 year ago

LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day

Nov 9, 2024, 1:16 AM EST - 1 year ago

LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

LENSAR Reports Third Quarter 2024 Results and Provides Business Update

Oct 31, 2024, 7:00 AM EDT - 1 year ago

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 8, 2024, 8:00 AM EDT - 1 year ago

One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems

Sep 4, 2024, 8:00 AM EDT - 1 year ago

LENSAR to Participate in Two Upcoming Investor Conferences

Aug 10, 2024, 12:15 AM EDT - 1 year ago

LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

LENSAR Reports Second Quarter 2024 Results and Provides Business Update

Aug 7, 2024, 7:00 AM EDT - 1 year ago

LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union

Aug 1, 2024, 7:00 AM EDT - 1 year ago

LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

May 23, 2024, 8:00 AM EDT - 1 year ago

LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

May 11, 2024, 3:50 PM EDT - 1 year ago

LENSAR, Inc. (LNSR) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

LENSAR Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Mar 4, 2024, 10:36 AM EST - 1 year ago

LENSAR, Inc. (LNSR) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 7:00 AM EST - 1 year ago

LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 26, 2024, 8:00 AM EST - 1 year ago

LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024

Nov 11, 2023, 12:32 PM EST - 2 years ago

LENSAR, Inc. (LNSR) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 7:00 AM EST - 2 years ago

LENSAR Reports Third Quarter 2023 Results and Provides Business Update

Nov 2, 2023, 8:03 AM EDT - 2 years ago

LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Aug 11, 2023, 6:04 PM EDT - 2 years ago

LENSAR, Inc. (LNSR) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 7:00 AM EDT - 2 years ago

LENSAR Reports Second Quarter 2023 Results and Provides Business Update

Aug 2, 2023, 8:00 AM EDT - 2 years ago

LENSAR to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

Jul 24, 2023, 7:00 AM EDT - 2 years ago

LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups

May 15, 2023, 10:25 AM EDT - 2 years ago

LENSAR, Inc. (LNSR) Q1 2023 Earnings Call Transcript

May 15, 2023, 7:00 AM EDT - 2 years ago

LENSAR Reports First Quarter 2023 Results and Provides Business Update

May 10, 2023, 8:00 AM EDT - 2 years ago

LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

Mar 16, 2023, 9:33 AM EDT - 2 years ago

LENSAR, Inc. (LNSR) Q4 2022 Earnings Call Transcript

Mar 16, 2023, 7:00 AM EDT - 2 years ago

LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Mar 9, 2023, 8:00 AM EST - 3 years ago

LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

Feb 14, 2023, 7:00 AM EST - 3 years ago

LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results

Nov 22, 2022, 8:00 AM EST - 3 years ago

LENSAR to Present at Two Upcoming Investor Conferences

Nov 12, 2022, 11:29 AM EST - 3 years ago

LENSAR, Inc. (LNSR) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 7:00 AM EST - 3 years ago

LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 2, 2022, 8:00 AM EDT - 3 years ago

LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022

Sep 8, 2022, 7:00 AM EDT - 3 years ago

LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU

Aug 16, 2022, 7:00 AM EDT - 3 years ago

First Patients Treated with LENSAR's® ALLY™ Adaptive Cataract Treatment System

Aug 8, 2022, 10:59 AM EDT - 3 years ago

LENSAR, Inc. (LNSR) CEO Nicholas Curtis on Q2 2022 Results - Earnings Call Transcript

ap20 Dec. 4 at 7:32 PM

$LNSR Buying back today. I don’t know much about the FTC, but just don’t think they care much about a $166M deal. We will see..

0 · Reply

BEATOFtheMARKET Nov. 25 at 8:02 PM

$LITE $LLY $LLYX $LMND $LNSR

0 · Reply

BEATOFtheMARKET Nov. 22 at 9:31 PM

$LITE $LLY $LLYX $LMND $LNSR

0 · Reply

RocketThief Nov. 7 at 3:59 PM

$LNSR now cheaper than when the Alcon deal was announced. Very interesting situation

1 · Reply

MarketCraze Oct. 5 at 10:18 AM

$LNSR Technology services niche. Thin volume trading. No technical edge. Avoid.

0 · Reply

NVDAMillionaire Sep. 9 at 8:30 AM

0 · Reply

RocketThief Aug. 14 at 8:00 PM

$LNSR nice spot for a small swing - would be surprised if the merger doesn’t happen

0 · Reply

d_risk Aug. 8 at 11:51 AM

0 · Reply

PenkeTrading Jun. 6 at 2:13 PM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of LENSAR Inc. Is that bullish or bearish? $LNSR #LENSAR #RsiOversold #NASDAQ

0 · Reply

HypnoTrader Jun. 5 at 6:58 PM

$LNSR merger caput?

0 · Reply

QuiverQuant Jun. 2 at 9:50 PM

LENSAR, Inc. Grants 3,090 Restricted Stock Units to New Employees as Inducement for Employment Read more on $LNSR: https://www.quiverquant.com/news/LENSAR%2C+Inc.+Grants+3%2C090+Restricted+Stock+Units+to+New+Employees+as+Inducement+for+Employment

0 · Reply

HypnoTrader May. 24 at 1:58 AM

$LNSR They get a delay in the merger from FTC and do not bother issuing a press release. WTF? No wonder the stock dropped....

0 · Reply

Chiroptera_Capital Apr. 16 at 8:55 PM

$SIBN medtech M&A is heating up. $LNSR and $ICAD are two medtech nanocaps that have been taken out in 2025. Si-Bone in 2026?

1 · Reply

Chiroptera_Capital Apr. 16 at 3:47 AM

$ICAD $LNSR both acquired… I’m wrong plenty but this call feels good

1 · Reply

smartkarma Apr. 14 at 1:20 AM

$LNSR | Strategic Acquisitions, Merger Developments, and Takeover Bids: Key Updates "Lensar (LNSR) is being acquired by Alcon for $14/share plus a CVR up to $2.75/share, with closing expected in H2 2024. OCI N.V. announced a $1BN extraordinary cash distribution..." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/strategic-acquisitions-merger-developments-and-takeover-bids-key-updates

0 · Reply

smartkarma Apr. 10 at 10:39 AM

$LNSR | Alcon's Strategic Acquisition of Lensar: Potential 23% Upside with CVR Payout and Antitrust Considerations "Lensar is being acquired by Alcon for $14/share in cash plus a CVR worth up to $2.75/share." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/alcon-s-strategic-acquisition-of-lensar-potential-23-upside-with-cvr-payout-and-antitrust-considerations

0 · Reply

NVDAMillionaire Mar. 29 at 1:34 AM

Digging ALLY System's potential. FDA clearance in 2022 looks promising. Robotic tech could disrupt cataract surgery market. Watching closely for next quarter's performance. $LNSR might be an interesting play. essential takeaways from recent developments: https://beyondspx.com/article/lensar-inc-nasdaq-lnsr-a-robotic-revolution-in-cataract-treatment

0 · Reply

OpenOutcrier Mar. 24 at 8:01 PM

RECAP 3/24 +Pos Comments: $TSLA + New Street RECAP 3/24 -Neg Comments: $DOOO - Edgwater Research $DOCS - Lauren Balik $OPT - Oppy $LNSR - Lake St Capital Live Breaking trading news www.openoutcrier.com

0 · Reply

JarvisFlow Mar. 24 at 4:19 PM

Lake Street updates rating for LENSAR ( $LNSR ) to Hold, target set at 16 → 15.

0 · Reply

HypnoTrader Mar. 24 at 3:43 PM

$LNSR so the market is valuing potential $2.75 at the end of 2027 + 3 months interest rate of $14 + potential for additional higher bids at a combined $. 32 premium to the buyout price of $14... fair enough.

0 · Reply

HypnoTrader Mar. 24 at 1:30 PM

$LNSR definitely a lawsuit. Class action, settlement. Maybe $500K to lawyers, 5-6 cents to shareholders... this is how it goes.

0 · Reply

Market Cap	137.49M
Revenue (ttm)	53.49M
Net Income (ttm)	-31.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-58.70%
Debt to Equity Ratio	0.00

Volume	58,600
Avg Vol	58,808
Day's Range	N/A - N/A
Shares Out	11.95M
Stochastic %K	88%
Beta	0.66
Analysts	Hold
Price Target	$15.00